Skip to main content
Displaying 1 - 12 of 24
Display:
12
24
48
Viral Hepatitis
1
GSK: Time to rethink chronic hepatitis B: A roadmap to functional cure (Complete Session) - EASL Congress 2024
View
Viral Hepatitis
1
GSK: Time to rethink chronic hepatitis B: Quantitative hepatitis B surface antigen today and tomorrow (Complete Session) - EASL Congress 2024
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
5
Gilead: See B, think D: lighting the path forward to innovative treatment in hepatitis delta - ILC 2022
View
Viral Hepatitis
2
GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021
View
Viral Hepatitis
2
GSK: HBsAg clearance in chronic hepatitis B: How close is it? - ILC 2021
View
Viral Hepatitis
6
Gilead Sciences: A new beginning in hepatitis delta - ILC 2021
View
Viral Hepatitis
6
Gilead Sciences: A new beginning in hepatitis delta - ILC 2021
View
Viral Hepatitis
6
Gilead Sciences: A new beginning in hepatitis delta - ILC 2021
View
Viral Hepatitis
6
Gilead Sciences: A new beginning in hepatitis delta - ILC 2021
View
Pagination
Current page
1
Page
2
Next page
next ›
Last page
Last »
©2019 - EASL. All Rights Reserved. Powered by
Enovation
.
Footer menu
Content Access policy
Privacy Policy
Cookie Policy